On January 12, 2026, Zymeworks appointed investment veteran Brian Cherry to its Board of Directors, expanding the board to nine members. Mr. Cherry brings over 25 years of private equity and growth-equity experience, having led transactions totaling more than $25 billion in enterprise value and served on over a dozen corporate boards. His expertise in capital allocation and strategic acquisitions complements recent board streamlining efforts, which reduced membership from twelve to nine, and follows the appointments of Oleg Nodelman, Greg Ciongoli and Robert E. Landry within the past year.

Effective February 1, 2026, Dr. Sabeen Mekan will assume the role of Chief Medical Officer, overseeing clinical development, regulatory affairs, pharmacovigilance and operations, succeeding Dr. Jeff Smith upon his retirement. Concurrently, Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer, broadening his remit to include alliance management and manufacturing operations. In the first quarter of 2026, CFO Leone Patterson and General Counsel Daniel Dex will depart, with CEO Kenneth Galbraith serving as Acting CFO while a permanent replacement is sought.

As part of its November corporate strategy, Zymeworks promoted or appointed five new vice presidents across human resources, finance, corporate development, translational sciences, investor relations, communications, treasury, tax and regulatory affairs. These changes coincide with the company’s $125 million share repurchase authorization announced in late 2025, and an unaudited cash, cash equivalents and marketable securities balance of approximately $270.6 million as of December 31, 2025, underpinning a cash runway beyond 2028 and positioning Zymeworks to fund both internal R&D and strategic asset acquisitions.